ATX
AMPLIA THERAPEUTICS LIMITED
$0.0830
▼ -7.78%
Market cap
$43M
Turnover
$27,289
Last price
$0.0830
Day change
-7.78%
Announcements
11
Range, past year
Open 0.115 · Low 0.049 · Now 0.083 · High 0.425
Open ATX in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
ATX momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
30/100
Wyckoff phase
Accumulation12d
Trend stage
Neutral
1 Day
-7.8%
1 Week
+1.2%
1 Month
+3.8%
1 Year
-36.2%
RSI
41
Avg daily range
7.4%
AMPLIA THERAPEUTICS LIMITED scores 30 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 12 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently matching and the institutional accumulation signal reads low.
What stands out
- Trend R² 0.88 — highly linear uptrend
Points to watch
- 60d drawdown -48.0%
- High volatility (ATR 7.4%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
ATX announcements
Recent price-sensitive releases.
- 2026-10-28 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Second Quarter Activity Report | Commitments Test Entity - Second Quarter Cashflow Report
- 2026-10-22 Amplia Receives R&D Tax Rebate Totalling $4.78 Million Progress Report | Company Administration - Other
- 2026-10-16 Response to ASX Price Query Response to ASX Query
- 2026-08-04 Amplia signs Collaboration and Supply Agreement with Lilly Progress Report
- 2026-07-29 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-05-29 Preliminary Final Report and Annual Report YE 31 March 2026
- 2026-05-19 Amplia Launches First Stage of Pivotal Narmafotinib Trial
More Health Care stocks
Most traded in the same sector.